Physician profile
Hunter A Stenzel
NPI 1134339278
$5,104.14
in general payments reported to CMS, 2019-2025
37 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $413 · 2021: $504 · 2022: $902 · 2023: $865 · 2024: $886 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,062.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $540.08 | 2019-2025 | Vraylar, Liletta, Qulipta |
| Amgen INC. | $494.24 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $298.64 | 2019-2025 | Veozah |
| Lilly USA, LLC | $266.63 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $258.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.28 | 2019-2025 | Jardiance |
| Pfizer INC. | $207.63 | 2022-2025 | |
| Corcept Therapeutics | $197.58 | 2023-2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $176.01 | 2021-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $169.51 | 2020-2025 | Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.22 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $141.99 | 2025 | Auvelity |
| Sage Therapeutics, LLC | $127.11 | 2024-2025 | Zurzuvae |
| Sanofi Pasteur INC. | $106.21 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $99.15 | 2019-2022 | |
| Cranial Technologies, INC | $61.09 | 2022-2025 | Doc Band |
| Bayer Healthcare Pharmaceuticals INC. | $56.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.03 | 2022 | |
| Sumitomo Pharma America, INC. | $39.31 | 2024 | Gemtesa |
| Mylan Pharmaceuticals INC. | $38.83 | 2022 | |
| Nevro Corp. | $37.26 | 2022-2023 | Senza |
| Dexcom, INC. | $34.03 | 2023-2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $29.20 | 2020 | |
| Coopersurgical, INC. | $26.70 | 2019-2022 | |
| Lundbeck LLC | $24.13 | 2025 | Rexulti |
| Organon LLC | $23.37 | 2025 | Nexplanon |
| Amarin Pharma, INC. | $18.66 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.15 | 2024 | Trulance, Xifaxan |
| Medtronic, INC. | $17.63 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $16.62 | 2024 | Gvoke Hypopen |
| Indivior INC. | $14.93 | 2019 | |
| Alkermes, INC. | $14.93 | 2019 | |
| Exact Sciences Corporation | $14.89 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $14.01 | 2021 | |
| Exeltis, USA INC. | $13.28 | 2024 | Slynd |
| Therapeuticsmd, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Stenzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.